Evidence map›Paper›PMID 26176218›Full record

ArticlePloS one2015

Short- versus Long-Sarafotoxins: Two Structurally Related Snake Toxins with Very Different in vivo Haemodynamic Effects.

Yazine Mahjoub, Stéphanie Malaquin, Gilles Mourier, Emmanuel Lorne, Osama Abou Arab, Ziad A Massy, Hervé Dupont, Frédéric Ducancel

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Toxins in disguise: Neuropeptide mimicry across animal venoms.General and comparative endocrinology · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Suppression of cardiomyocyte functions by β-CTX isolated from the Thai king cobra (The journal of venomous animals and toxins including tropical diseases · 2020
    Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yazine MahjoubPôle d'anesthésie, réanimation et médecine d'urgence, CHU Amiens, Amiens, France; Unité INSERM U1088, Amiens, France.
Stéphanie MalaquinPôle d'anesthésie, réanimation et médecine d'urgence, CHU Amiens, Amiens, France; Unité INSERM U1088, Amiens, France.
Gilles MourierCEA, iBiTec-S, Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), CEA Saclay, F-91191 Gif sur Yvette, France.
Emmanuel LornePôle d'anesthésie, réanimation et médecine d'urgence, CHU Amiens, Amiens, France; Unité INSERM U1088, Amiens, France.
Osama Abou ArabPôle d'anesthésie, réanimation et médecine d'urgence, CHU Amiens, Amiens, France; Unité INSERM U1088, Amiens, France.
Ziad A MassyUnité INSERM U1088, Amiens, France.
Hervé DupontPôle d'anesthésie, réanimation et médecine d'urgence, CHU Amiens, Amiens, France; Unité INSERM U1088, Amiens, France.
Frédéric DucancelCEA, iMETI, Service d'Immuno Virologie (SIV), CEA Fontenay-aux-Roses, F-92265 Fontenay-aux-Roses, France.
Inserm · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRCentre Hospitalier Universitaire Amiens-Picardie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledSarafotoxin-m (24 amino acids) from the venom of Atractaspis microlepidota microlepidota was the first long-sarafotoxin to be identified, while sarafotoxin-b (21 aa) is a short-sarafotoxin from Atractaspis engaddensis. Despite the presence of three additional C-terminus residues in sarafotoxin-m, these two peptides display a high sequence homology and share similar three-dimensional structures. However, unlike sarafotoxin-b, sarafotoxin-m shows a very low in vitro affinity for endothelin receptors, but still has a very high in vivo toxicity in mammals, similar to that of sarafotoxin-b. We have previously demonstrated, in vitro, the crucial role of the C-terminus extension in terms of pharmacological profiles and receptor affinities of long- versus short-sarafotoxins. One possible hypothesis to explain the high in vivo toxicity of sarafotoxin-m could be that its C-terminus extension is processed in vivo, resulting in short-like sarafotoxin. To address this possibility, we investigated, in the present study, the in vivo cardiovascular effects of sarafotoxin-b, sarafotoxin-m and sarafotoxin-m-Cter (sarafotoxin-m without the C -terminus extension). Male Wistar rats were anaesthetised and mechanically ventilated. Invasive haemodynamic measurements and echocardiographic measurements of left and right ventricular function were performed. The rats were divided into four groups that respectively received intravenous injections of: saline, sarafotoxin-b (one LD50), sarafotoxin-m (one LD50) or sarafotoxin-m-Cter (one LD50). All measurements were performed at baseline, at 1 minute (+1) and at 6 minutes (+6) after injection.

resultsSarafotoxin-b and sarafotoxin-m-Cter decreased cardiac output and impaired left ventricle systolic and diastolic function, whilst sarafotoxin-m decreased cardiac output, increased airway pressures and led to acute right ventricular dilatation associated with a decreased tricuspid annulus peak systolic velocity. Sarafotoxin-b and sarafotoxin-m-Cter appear to exert toxic effects via impairment of left ventricular function, whilst sarafotoxin-m increases airway pressures and impairs right ventricular function. These results do not support the hypothesis of an in vivo processing of long sarafotoxins.

Indexed as

Structural Homology, ProteinAnimalsEchocardiography, DopplerElectrocardiographyHeart RateHemodynamicsLungMalePressureRats, WistarReproducibility of ResultsVentricular FunctionViper VenomsViper Venoms

Identifiers

PMID26176218
PMCPMC4503772
OpenAlexW1604794166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.